These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies]. Ouallet JC Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382 [TBL] [Abstract][Full Text] [Related]
3. [Training program for patients with multiple sclerosis at the start of immunomodulatory therapy]. Harto-Castaño A Enferm Clin; 2007; 17(5):267-71. PubMed ID: 17961470 [TBL] [Abstract][Full Text] [Related]
5. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
7. [Current state of research on multiple sclerosis]. Lubina-Dabrowska N; Stepień A; Chalimoniuk M Pol Merkur Lekarski; 2013 Mar; 34(201):135-9. PubMed ID: 23700821 [TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Mahurkar S; Suppiah V; O'Doherty C Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284 [TBL] [Abstract][Full Text] [Related]
9. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Bates D Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678 [TBL] [Abstract][Full Text] [Related]
10. Modern multiple sclerosis treatment - what is approved, what is on the horizon. Pilz G; Wipfler P; Ladurner G; Kraus J Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508 [TBL] [Abstract][Full Text] [Related]
12. [Immunomodulatory effects of glatiramer acetate as they relate to stage-specific immune dysregulation in multiple sclerosis]. Yokoyama K; Hattori N Nihon Yakurigaku Zasshi; 2016 Aug; 148(2):105-20. PubMed ID: 27478050 [No Abstract] [Full Text] [Related]
13. Immunomodulatory drug treatment in multiple sclerosis. Aharoni R Expert Rev Neurother; 2010 Sep; 10(9):1423-36. PubMed ID: 20819013 [TBL] [Abstract][Full Text] [Related]
14. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis. Banwell B; Tremlett H Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408 [No Abstract] [Full Text] [Related]
15. Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis. Velazquez-Villoria D; Macia-Badia C; Segura-García A; Pastor Idoate S; Arcos-Algaba G; Velez-Escola L; García-Arumí J Arch Soc Esp Oftalmol; 2017 Jun; 92(6):273-279. PubMed ID: 28188020 [TBL] [Abstract][Full Text] [Related]
16. Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. Mendes A; Sá MJ Arq Neuropsiquiatr; 2011 Jun; 69(3):536-43. PubMed ID: 21755136 [TBL] [Abstract][Full Text] [Related]
17. Current approved options for treating patients with multiple sclerosis. Rizvi SA; Agius MA Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672 [TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory treatment of multiple sclerosis in Norway. Torkildsen Ø; Grytten N; Myhr KM Acta Neurol Scand Suppl; 2007; 187():46-50. PubMed ID: 17419828 [TBL] [Abstract][Full Text] [Related]
19. Established and novel disease-modifying treatments in multiple sclerosis. Cross AH; Naismith RT J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048 [TBL] [Abstract][Full Text] [Related]
20. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]